A third Phase 3 study of Engensis(VM-202) in Participants With Diabetic Peripheral Neuropathy
Latest Information Update: 16 Mar 2022
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Diabetic neuropathies
- Focus Registrational; Therapeutic Use
- Acronyms REGAiN-2A
- Sponsors Helixmith
Most Recent Events
- 16 Mar 2022 New trial record
- 14 Mar 2022 According to a Helixmith media release, the company planning to start this study in the second half of 2022.